MIFH
NRIX icon

Migdal Insurance & Financial Holdings’s Nurix Therapeutics NRIX Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-371
Closed -$11K – 664
2021
Q4 		$11K Sell
371
-224
-38% -$6.79K ﹤0.01% 590
2021
Q3 		$18K Buy
+595
New +$18.4K ﹤0.01% 562

Other funds holding NRIX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Migdal Insurance & Financial Holdings's NRIX Position: Q1 2022 in Review

Migdal Insurance & Financial Holdings sold out of Nurix Therapeutics (NRIX) in Q1 2022, closing a stake of 371 shares — an estimated $11K sold.

Migdal Insurance & Financial Holdings first reported a position in NRIX in Q3 2021 and held it in 2 quarters. The position peaked at $18K in Q3 2021. 117 funds tracked by Wall St. Rank hold NRIX as of Q1 2022.

  • Migdal Insurance & Financial Holdings reported no remaining Nurix Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 371 Nurix Therapeutics shares in Q1 2022, an estimated $11K.
  • Migdal Insurance & Financial Holdings first reported a position in Nurix Therapeutics in Q3 2021 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's Nurix Therapeutics position peaked at $18K in Q3 2021.
  • 117 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2022.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q1 2022, filed 2 May 2022.